Pharma-Bio Serv

pharmabioserv.com

Pharma-Bio Serv is the Life Sciences Industry Leader in regulatory compliance, validation, and other regulated industry support services. Founded in February 1993, Pharma-Bio Serv offers technical services, product and process transfers, commissioning, process engineering, and technology transfer, to pharmaceutical, medical devices, consumer, chemical and biotechnology industries in Puerto Rico, United States, Brazil and Europe.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

ASTORG TO ACQUIRE GLOBAL MEDICAL COMMUNICATIONS AND MARKET ACCESS PLATFORM OPEN HEALTH FROM AMULET CAPITAL PARTNERS

Astorg and Amulet Capital Partners | June 01, 2022

news image

Astorg and Amulet Capital Partners announce that they have signed a binding agreement whereby Astorg will acquire OPEN Health, a leading global provider of scientific communications and market access services to the pharmaceutical industry. Established in 2011 and headquartered in London, UK, OPEN Health is a key partner to its customers in helping them develop strategies for evidence generation and data communication by leveraging their extensive scientific knowledge and relentle...

Read More

PHARMACY MARKET

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

news image

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More

PHARMA TECH

XERIS BIOPHARMA ANNOUNCES RESEARCH COLLABORATION AND OPTION AGREEMENT WITH HORIZON THERAPEUTICS PLC FOR XERIJECT™ FORMULATION OF TEPROTUMUMAB

Xeris | November 24, 2022

news image

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc. Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect™, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of tepr...

Read More

ALLIANCE FOR REGENERATIVE MEDICINE PUBLISHED ITS RESPONSE TO EU PHARMACEUTICAL ROADMAP

Alliance for Regenerative Medicine | July 07, 2020

news image

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. The full response can be found on the European Commission website. While A...

Read More
news image

BUSINESS INSIGHTS

ASTORG TO ACQUIRE GLOBAL MEDICAL COMMUNICATIONS AND MARKET ACCESS PLATFORM OPEN HEALTH FROM AMULET CAPITAL PARTNERS

Astorg and Amulet Capital Partners | June 01, 2022

Astorg and Amulet Capital Partners announce that they have signed a binding agreement whereby Astorg will acquire OPEN Health, a leading global provider of scientific communications and market access services to the pharmaceutical industry. Established in 2011 and headquartered in London, UK, OPEN Health is a key partner to its customers in helping them develop strategies for evidence generation and data communication by leveraging their extensive scientific knowledge and relentle...

Read More
news image

PHARMACY MARKET

STANDIGM SIGNS MOU WITH MERCK KOREA FOR AI DRUG DISCOVERY RESEARCH

Standigm | June 02, 2022

Standigm Inc. the leading workflow artificial intelligence (AI) drug discovery company, announced the signing of a Memorandum of Understanding (MOU) with Merck Korea, for AI-based drug discovery research. The MOU signing took place on May 30 at the headquarters of Standigm, attended by Sojeong Yun, CEO of Standigm, and Stephen Namkoo Lee, the Head of Science and Lab Solutions, Life Science business sector of Merck Korea. Under the MOU, Standigm will accelerate its drug discovery r...

Read More
news image

PHARMA TECH

XERIS BIOPHARMA ANNOUNCES RESEARCH COLLABORATION AND OPTION AGREEMENT WITH HORIZON THERAPEUTICS PLC FOR XERIJECT™ FORMULATION OF TEPROTUMUMAB

Xeris | November 24, 2022

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc. Under the terms of the agreement, Xeris will use its proprietary formulation technology platform, XeriJect™, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of tepr...

Read More
news image

ALLIANCE FOR REGENERATIVE MEDICINE PUBLISHED ITS RESPONSE TO EU PHARMACEUTICAL ROADMAP

Alliance for Regenerative Medicine | July 07, 2020

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. The full response can be found on the European Commission website. While A...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us